A new hope for sufferers and victims of Karenism: FDA approves groundbreaking treatment called Karganon.
Today the FDA has approved the first-ever drug to treat Karenism. The new drug, called Karganon, was developed by a small biotechnology firm called Quartarix. Karganon is a small molecule inhibitor, which means it works by blocking the activity of the mutant PHAKY gene. This helps to restore normal function and stops its progression. Rumors have it the government will be subsidizing its cost and should be available for free at most pharmacies.
The FDA approval is based on data from a small clinical trial that showed it was safe and effective in treating Karenism. Patients who took the drug showed significant improvements. The trial included 11 patients named Karen, although 4 of the patients spelled their name with an "i" (Karin) which has sparked additional controversy about the approval.
The FDA's decision is a welcome sign of progress for families affected by Karenism, and offers hope that it can be managed and treated. It is a vital step in improving the quality of life for Karenism patients and their families and gives those affected hope for the future.